See more : Kissei Pharmaceutical Co., Ltd. (KSPHF) Income Statement Analysis – Financial Results
Complete financial analysis of Sinew Pharma Inc. (6634.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sinew Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Eureka Industries Limited (EUREKAI.BO) Income Statement Analysis – Financial Results
- Vision Hydrogen Corporation (VIHD) Income Statement Analysis – Financial Results
- Quebec Precious Metals Corporation (QPM.V) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (JPM-PJ) Income Statement Analysis – Financial Results
- Egetis Therapeutics AB (publ) (EGTX.ST) Income Statement Analysis – Financial Results
Sinew Pharma Inc. (6634.TWO)
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 328.00K | 6.23M | 462.00K | 0.00 |
| Cost of Revenue | 28.99M | 38.00K | 1.14M | 138.00K | 0.00 |
| Gross Profit | -28.99M | 290.00K | 5.09M | 324.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 88.41% | 81.75% | 70.13% | 0.00% |
| Research & Development | 133.46M | 114.62M | 72.75M | 66.71M | 60.29M |
| General & Administrative | 34.75M | 34.10M | 26.77M | 17.73M | 16.55M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.75M | 34.10M | 26.77M | 17.73M | 16.55M |
| Other Expenses | 0.00 | 150.00K | 40.00K | 2.00K | 10.00K |
| Operating Expenses | 186.25M | 148.72M | 99.51M | 84.43M | 76.84M |
| Cost & Expenses | 186.25M | 148.76M | 100.65M | 84.57M | 76.84M |
| Interest Income | 0.00 | 8.37M | 2.95M | 2.37M | 783.00K |
| Interest Expense | 0.00 | 275.00K | 146.00K | 274.00K | 176.00K |
| Depreciation & Amortization | 22.62M | 22.81M | 22.64M | 21.86M | 18.26M |
| EBITDA | -163.63M | -117.09M | -68.79M | -59.88M | -57.79M |
| EBITDA Ratio | 0.00% | -35,698.78% | -1,104.27% | -12,961.26% | 0.00% |
| Operating Income | -186.25M | -139.91M | -91.43M | -81.74M | -76.05M |
| Operating Income Ratio | 0.00% | -42,653.96% | -1,467.80% | -17,691.99% | 0.00% |
| Total Other Income/Expenses | 15.33M | 8.25M | 2.85M | 2.10M | 617.00K |
| Income Before Tax | -170.92M | -140.18M | -91.58M | -82.01M | -76.23M |
| Income Before Tax Ratio | 0.00% | -42,737.80% | -1,470.14% | -17,751.30% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -170.92M | -140.18M | -91.58M | -82.01M | -76.23M |
| Net Income Ratio | 0.00% | -42,737.80% | -1,470.14% | -17,751.30% | 0.00% |
| EPS | -2.43 | -2.02 | -1.54 | -1.60 | -1.94 |
| EPS Diluted | -2.43 | -2.02 | -1.54 | -1.60 | -1.94 |
| Weighted Avg Shares Out | 70.34M | 69.30M | 59.50M | 51.29M | 39.37M |
| Weighted Avg Shares Out (Dil) | 70.46M | 69.30M | 59.50M | 51.29M | 39.37M |
Source: https://incomestatements.info
Category: Stock Reports